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A multi screen serum analysis program has been de-
veloped that permits a determination of antibody speci-
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ficity for the vast majority of highly sensitized patients 
awaiting transplantation. This program is based on a 2 
x 2 table analysis of correlations between serum reac-
tivity with an HLA-typed cell panel and incorporates 
two modifications. One implements the concept of public 
HLA determinants based on the serologic crossreactivity 
among class I HLA antigens. The other modification 
derives from the premise that most highly sensitized 
patients maintain the same PRA and antibody profiles 
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over many months and even years. Monthly screening 
results for patients with persistent PRA values can 
therefore be combined for analysis. 
For 132 of 150 highly sensitized patients with >50% 
PRA, this multiscreen serum analysis program yielded 
information about antibody specificity toward public 
and private class I HLA determinants. The vast majority 
of patients (108 of 112) with PRA values between 50 
and 89% showed antibody specificity generally toward 
one, two, or three public markers and/or the more com-
mon private HLA-A,B antigens. For 24 of 38 patients 
with >90% PRA, it was possihle to define one or few 
HLA-specific antibodies. 
The primary objective of the multiscreen program was 
to develop an algorithm about computer-predicted ac-
ceptable and unacceptable donor HLA-A,B antigens for 
patients with preformed antibodies. A retrospective 
analysis of kidney transplants into 89 highly sensitized 
patients has demonstrated that allografts with unac-
ceptable HLA-A,B mismatches had significantly lower 
actuarial survival rates than those with acceptable mis-
matches (P = 0.01). This was shown for both groups of 
32 primary transplants (44% vs. 67% after 1 year) and 
60 retransplants (50% vs. 68%). Also, serum creatinine 
levels were significantly higher in patients with unac-
ceptable class I mismatches (3.0 vs. 8.4 mg% [P = 0.007] 
after 2 weeks; 3.9 vs. 9.1 mg% [P = 0.014] after 4 
weeks). Histopathologic analysis of allograft tissue spec-
imens from 47 transplant recipients revealed a signifi-
cantly higher incidence of humoral rejection (P = 0.02), 
but not cellular rejection, in the unacceptable mismatch 
group. These results suggest that the multiscreen pro-
gram can establish which donor HLA-A,B mismatches 
must be avoided in kidney transplantation for most 
highly sensitized patients. 
For 18 of 150 high PRA renal dialysis patients, the 
multiscreen program could not define HLA-specific an-
tibody. Most patients had >90% PRA, and many of their 
sera appeared to contain IgM type nonspecific lympho-
cytotoxins that could be inactivated by dithioerythreitol 
(DTE). Preliminary studies have shown that this treat-
ment enabled the detection of HLA-specific antibodies 
upon subsequent screening on many occasions. These 
data suggest that non-HLA specific reactivity revealed 
by multiscreen analysis can often be removed by DTE 
treatment. 
Multiscreen analysis offers an attractive approach to 
regional organ-sharing programs for highly sensitized 
renal transplant candidates. It enables the development 
of an efficient strategy for donor selection based on the 
computer assignment of acceptable HLA-A,B mis-
matches for each patient. 
The highly sensitized renal dialysis patient presents an 
enigma to most transplant programs. Not only is it difficult to 
find a suitable crossmatch negative donor, but it is also appar-
ent that a kidney transplant is generally less successful (1-3). 
The accumulation of highly sensitized patients on renal trans-
plant waiting lists is a universal problem (4, 5). 
Many sensitized patients have HLA-specific antibodies due 
to previous graft failures, blood transfusions, and pregnancies. 
Humoral sensitization is determined by testing patient sera in 
lymphocytotoxicity assays against a cell panel from HLA-typed 
donors. These assays are designed to primarily detect antibod-
ies specific for the products of the HLA-A and HLA-B loci. 
Patients with panel-reactive-antibody activity of greater than 
50% are considered highly sensitized. The higher the PRA 
value, the more difficult it is to find a crossmatch negative 
donor. The chances of a successful transplant are improved by 
selecting HLA-A and HLA-B identical or compatible donors, 
but the extensive polymorphism of HLA limits this approach. 
Another approach is via desensitization protocols aimed at 
reducing antibody levels by plasmapheresis in combination 
with immunosuppressive drugs (6) or with immunoabsorbent 
columns (7). Alternatively, several collaborating transplant 
programs have implemented the distribution of high PRA sera 
among tissue-typing laboratories to identify negative cross-
matches with random potential donors by trial and error (5, 8, 
9). 
Another strategy utilizes the screening of high PRA sera with 
specifically selected panel cells to determine which HLA-A and 
HLA-B antigen mismatches might be considered acceptable 
because they do not cause a positive crossmatch (10, 11). This 
approach has been successfully applied in kidney transplanta-
tion but is very labor intensive and requires access to an 
extremely large panel of HLA typed donors. 
The HLA antibody specificities of high PRA sera have been 
analyzed by absorption and elution studies using selected HLA 
typed cells (12, 13). These antibodies can be categorized ac-
cording to specificity toward private and public determinants. 
Each private determinant represents a unique epitope config-
uration on one HLA gene product, whereas a public determi-
nant represents an epitope shared by more than one HLA gene 
product (14). Antibodies against public determinants have been 
used to classify HLA antigens into several major crossreactive 
groups (CREGs).* Historically, high PRA sera have been as-
sumed to be multispecific, but it has become apparent that 
these sera generally contain a limited number of antibodies 
directed against public and private determinants of high fre-
quency (15). Differential absorption-elution studies will gen-
erally enable a dissection of the specific antibody subsets, 
thereby permitting an assessment of which mismatched HLA 
antigens of the donor would be acceptable to the patient (13). 
This method of serum analysis is also labor intensive and time 
consuming and requires considerable serologic expertise not 
available in most laboratories on a routine basis. 
In this report we describe a computer approach for analysis 
of high PRA sera for antibody specificities toward private and 
public HLA determinants. Assignments of public markers to 
panel cells are based on serologic crossreactivity among HLA-
A and HLA-B antigens. An algorithm then categorizes mis-
matched donor HLA-A,B antigens as acceptable or unaccept-
able to each highly sensitized patient. A retrospective analysis 
has shown that highly sensitized patients experience lower 
success rates with kidney transplants from donors with unac-
ceptable mismatches than from those with acceptable HLA-
A,B mismatches. 
These findings demonstrate that this computerized analysis 
to determine HLA antibody specificity of high PRA sera might 
be valuable in strategies to identify suitable transplant donors 
for highly sensitized patients. 
MATERIALS AND METHODS 
Patients. This study was done on 150 renal dialysis patients with 
persistent PRA values of greater than 50%. There were 62 patients 
* Abbreviations: CREGs, crossreactive groups; DTE, dithioerythrei-
tol; DTT, dithiothreitol. 
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who had not received a transplant and 88 patients with one or more 
previous failed allografts. No attempt was made to document their 
blood transfusion histories or previous pregnancies. The PRA values 
were distributed into four groups: 50-69% (n = 36), 70-79% (n = 29), 
80-89% (n = 47), and 90-100% (n = 38). Ninety-two kidney transplants 
were performed in this group of patients, and all 89 recipients received 
cyclosporine as the primary immunosuppressive drug. Transplant out-
come was evaluated as actuarial graft survivals during the first 360 
days. Serum creatinine levels at 2 and 4 weeks after transplantation 
were used to assess allograft function. 
Renal histopathology was done on 108 specimens from 47 transplants 
during the first 120 days posttransplant although most were taken 
during the first month. Needle biopsies and nephrectomy specimens 
were obtained when clinically indicated and processed routinely for 
light microscopy and, where feasible, for immunofluorescence using 
commercial antibodies to IgG, IgM, Clq, C3, and fibrinogen as previ-
ously described (16). For histologic evaluation, vascular lesions were 
classified as due to humoral or cellular rejection. Humoral rejection 
was diagnosed with multifocal fibrinoid necrosis, thrombosis, and 
polymorphonuclear leukocytes in the microvasculature. Positive fluo-
rescence was considered supportive evidence but was not necessary for 
the diagnosis. Vascular involvement in cellular rejection was charac-
terized by endothelial cell wall adhesions or infiltrates of mononuclear 
cells with or without fibrinoid necrosis. 
Histocompatibility testing. HLA-A,B typing was performed by the 
Amos modified lymphocytotoxicity technique, and HLA-DR typing 
was done by two-color fluorescence using standard methods. No con-
sideration was given to HLA-C polymorphisms. The Amos wash tech-
nique was also used for antibody screening of patient sera against 45-
60 cell panels from HLA typed individuals and for crossmatching 
against donor lymphocytes. Selected sera with non-HLA specific anti-
body activity were treated with dithioerythreitol (DTE) to inactivate 
IgM type lymphocytotoxins (17). This was done by treating 100 ILl of 
serum with 5 ILl of 100 mM DTE in RPMI-1640 medium at 37°C for 
30 min. 
Computer program for serum screening analysis. Serum reactivity 
and specificity against a cell panel were analyzed by computer (IBM 
PS/2 model 70) using custom software. This program generates a list 
of panel cells grouped according to their cytotoxicity scores with a 
patient's serum. Using 2 x 2 table statistics, antibody specificities were 
determined from correlations of positive reactions with the presence of 
private and public HLA determinants on the panel cells. This computer 
program generates for each serum a list of antibody specificities, 
generally no more than three or four with significant x2 values. Com-
puter assignment of the primary antibody specificity is based on the 
positive correlation with the highest x2 value. For the remaining serum 
reactions, a second antibody specificity is assigned by x2 analysis of 
correlations between reactions and the HLA specificities in the cell 
panel excluding those cells with the marker recognized by the first 
antibody. A third antibody specificity is determined from serum reac-
tivity patterns with panel cells except those with antigens recognized 
by the first and second antibody. This tail analysis is repeated until all 
positive reactions of the serum had been accounted for. Information is 
also generated about the undefined tail, i.e., the number of positive 
reactions that cannot be significantly correlated with any marker 
defined in the cell panel. 
Assignment of public markers. This is based on generally available 
information on serologic crossreactivity among class I HLA antigens, 
reviewed by Rodey and Fuller (14) and derived from our own experi-
ence. Computer-assigned public markers have a "P" prefix except those 
with low frequencies. For instance, the public marker POI is assigned 
to all panel cells typed for the private antigens AI, A3, All, and/or 
Aw36; these antigens are well known for crossreactivity among them-
selves. P02 is assigned to cells positive for the crossreacting A2 and 
A28 (including the Aw68 and Aw69 subtypes). Our current list of 
computer-assigned public markers and their included HLA antigens is 
shown in Table 1. Each panel cell used for serum screening is auto-
matically assigned by computer a set of P markers from its HLA-A,B 
type according to Table 1. For instance, the HLA-A1,3;B7,8(Bw6) 
phenotype is assigned with the following series: POl;Pll;P21, 
P22;P32;P42,P43;P62,P63;P71;P91,P92,P93,P94,P95 whereas A2,-; 
B51,44 (Bw4) is assigned with P02;P12;P22;P32;P41;P51;P61, 
P64;P72;P81,P82;P92. 
Table 1 also shows the relationship of the public markers to the 
major CREGs. For instance, POI, PH, P2l, P3l, P71, P91, and P93 
belong to the Al CREG. These P markers are all interrelated, i.e., PH 
= POI + AlO + Aw19; P71 = POI + A10 + A9; P93 = Pll + A28, etc. 
Multiple P markers within each CREG have increased the efficiency 
of the computer analysis program in detecting antibody specificities of 
high PRA sera. Three markers-P21, P22, and P92-were based on 
specificity patterns of class I specific murine monoclonal antibodies 
(18). 
This computer program also incorporates low-frequency public 
markers generally comprising two or a few HLA antigens. They are 
listed as three- or four-digit number combinations, e.g., 3031 is A30 + 
A31; 2532 = A25 + A32; 311 = A3 + All, etc. As negative controls, 
this program also designates "nonsense" markers (N97, N98, and N99) 
representing combinations of HLA antigens not belonging to recog-
nized CREGs. 
Statistical analysis. Antibody-specificity assignments were based on 
2 x 2 table analysis using x2 statistics to determine significant corre-
lations between serum reactivity patterns and the presence of specific 
markers in the cell panel. Actuarial renal transplant survivals were 
analyzed by generalized Wilcoxon (Gehan) statistics using Stata Re-
lease 2 software (Computing Resource Center, Los Angeles, CAl. Other 
differences between groups were analyzed for statistical significance 
with the Mann-Whitney U test, Students' t test, or by x2 analysis 
(Statview 512+, Macintosh microcomputer). 
RESULTS 
Results of monthly serum screens. Monthly serum specimens 
from renal dialysis patients were screened against cell panels 
from 45 to 60 HLA typed donors. For most sensitized patients, 
the serum PRA values vary only slightly from month to month. 
In 159 patients with greater than 50% PRA during at least 6 
months, we identified 150 patients with similar reactivity pat-
terns in their sera. For many high PRA sera, the computer 
analysis showed one or few antibody specificities, primarily 
toward public markers. 
Table 2 shows typical examples of monthly PRA values and 
computer-assigned antibody specificities based on highest x2 
values. Patient 21632 with serum PRA values in the 80-90% 
range exhibited consistent antibody specificity toward P32, a 
public determinant of the A2 CREG. The high PRA sera from 
patient 17793 reacted toward a public marker in the Al CREG, 
although no exact assignment could be made. An example of a 
dual antibody specificity is presented by patient 7145 whose 
sera consistently reacted with the Bw4-associated P81 and the 
Al CREG-associated P21 markers. For many patients with 
greater than 90% PRA, we could obtain information about 
possible antibody specificities, but the x 2 values of the 2 x 2 
correlations were not statistically significant due to the small 
size of the cell panels in the monthly screens. An example is 
patient 18358 whose sera seemed to react toward P8I, P42, and 
perhaps P22. Conversely, other high PRA patients like 25064 
repeatedly failed to display any tendency toward a specific 
antibody. The inability to assign HLA antibody specificity for 
some high PRA sera could be due to non-HLA specific lympho-
cytotoxicity or the inadequate size of our cell panel or both. 
Antibody-specificity analysis of multiscreens. The data in Ta-
ble 2 illustrate our experience that from month to month most 
highly sensitized patients show similar PRA values and pat-
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TABLE 1. Computer-assigned public specificities and their corresponding HLA antigen groups 
CREG 
POI IC 
P02 2C 
P03 1C 
Pll 1C 
P12 2C 
P21 1C 
P22 2C 
P31 lC 
P32 2C 
P4l 5C 
P42 7C 
P43 8C 
P51 5C 
P52 7C 
P61 5C 
P62 7C 
P63 8C 
P64 12C 
P71 lC 
P72 12C 
P81 4C 
P82 12C 
P91 lC 
P92 8C 
P93 1C 
P94 6C 
P95 8C 
Low-frequency groups: 
3031 lC 
2532 1C 
311 Ie 
1126 lC 
722 7C 
727 7C 
740 7C 
1340 7C 
1213 12C 
1221 12C 
814 8C 
1517 5C 
217 2C 
1622 8C 
"Nonsense" specificities: 
N97 
N98 
N99 
Included HLA-A, B antigens 
AI, A3, All, Aw36 
A2, A28, Aw68, Aw69 
A25, A32, Aw33, Aw66 
AI, A3, AlO, All, Aw19, Aw36, A25, A26, A29, A30, A31, A32, Aw33, Aw34, Aw66, Aw74 
A2, A9, A28, A23, A24, Aw68, Aw69 
AI, A9, AlO, All, A23, A24, A25, A26 (defined by moAb) 
A2, A3, A28, A30, A31, A32, Aw68, Aw69 
A26, A28, Aw33, Aw34, Aw68, Aw69, Aw74 
AI, A2, A9, A23, A24, A28, Aw68, Aw69 
B5, B15, B17, B18, B21, B35, Bw53, Bw70, B49, Bw50, B51, Bw52, Bw57, Bw58, Bw62, Bw63, 
Bw71, Bw72, Bw75, Bw76, Bw77 
B7, Bw22, B27, B40, Bw41, B42, Bw46, Bw47, Bw48, Bw73, Bw54, Bw55, Bw56, Bw60, Bw61 
B8, B14, B16, B38, B39, Bw59, Bw64, Bw65, Bw67 
B5, B15, Bl8, B35, Bw53, B5l, Bw52, Bw62, Bw63, Bw75, Bw76, Bw77 
BI3, B27, B40, Bw41, Bw47, Bw60, Bw61 
B5, B35, Bw53, B51, Bw52 
B7, Bw22, B27, Bw42, Bw54, Bw55, Bw56 
B8, B14, B18, Bw59, Bw64, Bw65 
B12, B21, B40, B44, B45, B49, Bw50, Bw60, Bw61 
AI, A3, A9, A10, All, A23, A24, A25, A26 
B5, B12, B13, B17, B21, B27, B37, B38, B40, Bw47, B51, Bw63, B44, B45, B49, Bw50, Bw57, 
Bw58, Bw60, Bw61 
A9, A23, A24, A32, Bw4 
B12, B13, B21, B27, B37, B40, Bw47, Bw41, B44, B45, B49, Bw50, Bw60, Bw61 
AI, AlO, A11, A32, A25, A26 
B8, B14, B18, B51, Bw59, Bw64, Bw65 (defined by moAb) 
AI, A3, A10, A11, Aw19, A28, Aw36, A25, A26, A29, A30, A31, A32, Aw33, Aw34, Aw66, Aw68, 
Aw69, Aw74 
All, Bw6 
B8, B14, BI6, Bw22, B38, B39, Bw54, Bw55, Bw56, Bw64, Bw65, Bw67 
A30, A31 
A25, A32 
A3, A11 
A11, A26 
B7, Bw22, Bw54, Bw55, Bw56 
B7, B27 
B7, B40, Bw60, Bw61 
B13, B40, B60, B61 
B12, B13, B44, B45 
B12, B21, B44, B45, B49, Bw50 
B8, B14, Bw64, Bw65 
B15, B17, Bw57, Bw58, Bw62, Bw63, Bw70, Bw71, Bw72, Bw75, Bw76, Bw77 
A2, B17, Bw57, Bw58 
B16, Bw22, B38, B39, Bw54, Bw55, Bw56, Bw67 
AI, A23, A25, A29, B5, B40, B45, Bw60, Bw61 
A2, All, A29, B7, B14, B15, B37, B44, Bw64, Bw65 
A24, A26, A32, B8, B13, B35, B44, Bw57 
terns of panel reactivity. This suggests that such patients 
maintain in their sera the same antibody-specificity profile. 
This experience is consistent with findings reported by Old-
father et al. (12, 16) and others (19, 20). Therefore, it was 
decided to combine monthly screening results for each patient, 
for up to a 12-month period. The consequent larger number of 
panel cells in these multi screens enabled a better statistical 
analysis of the specificity of antibody-reactivity patterns, yield-
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ing higher x2 values. Table 3 summarizes the results of multi-
screens on the five patients whose monthly screening data are 
shown in Table 2. For four patients, the antibody-reactivity 
patterns correlated with one or two public markers with very 
high x2 values. A multiscreen of eleven monthly serum speci-
mens from patient 21632 indicated mono specific antibody ac-
tivity toward P32, whereas a multiscreen on six monthly sera 
from patient 17793 showed antibody specificity against P93. 
Patient 7145, with a multiscreen PRA of 87%, showed two 
readily identifiable antibody specificities toward P81 and P21. 
For these patients, the multiscreens generated essentially the 
same information about antibody specificity as did the individ-
ual monthly screens. However, multiscreens yield considerably 
higher x2 values, thereby enabling more definite conclusions 
about the antibody specificity of high PRA sera. This is even 
better illustrated by the multiscreen of patient 18358 whose 
monthly screens yielded no statistically significant correlations 
regarding antibody activity. A multiscreen on six monthly 
specimens from patient 18358 showed a well-defined dual spec-
ificity toward P81 and P42. Conversely, multiscreens on certain 
patients failed to reveal antibody specificity to any defined 
public or private HLA-A,B marker. An example is patient 25064 
whose 93% PRA appeared to represent a non-HLA-specific 
lymphocytotoxic antibody. 
Summary of multiscreen results. For 132 of 150 highly sen-
sitized patients (or 88 %), it was possible to obtain information 
about HLA-specific antibody in their sera. For these patients 
the multiscreens were done on the most recent sera (n=61) or 
just prior to transplantation (n=89). Figure 1 shows the per-
centages of patients within different PRA ranges for which one 
or few HLA antibody specificities were identified. Antibody 
assignment was based on 2 X 2 analysis yielding x2 > 10.9 (or 
P<O.OOl). The vast majority of patients (108 of 112) with PRA 
values between 50% and 89% yielded specific HLA antibody 
TABLE 2. Examples of screening results of monthly serum specimens from highly sensitized renal dialysis patients 
Patient 
HLA 
21632 
A3,-
B8,-
DR5,8 
17793 
A2,-
B39,44 
DR5,-
7145 
A2,3 
B7,35 
DR2,6 
18358 
A2,3 
B8,39 
DR3,6 
25064 
A3,-
B7,-
DR2,-
Patient 
21632 
17793 
7145 
18358 
25064 
Serum 
date 
11/87 
12/87 
02/88 
03/88 
05/87 
08/87 
10/87 
12/87 
01/88 
08/88 
10/88 
12/88 
02/89 
04/89 
04/88 
11/88 
01/89 
02/89 
03/89 
01/87 
02/87 
09/87 
10/87 
PRA 
91% 
85% 
79% 
84% 
80% 
91% 
78% 
70% 
76% 
90% 
82% 
90% 
89% 
92% 
90% 
97% 
97% 
94% 
99% 
95% 
91% 
96% 
95% 
Monthly 
interval 
10/87-06/88 
01/87-12/87 
07/88-04/89 
03/88-02/89 
01/87-12/87 
ABl 
P32 
P32 
P32 
P32 
P21 
Pll 
P93 
POI 
P71 
P21 
P81 
P81 
P81 
P81 
P81 
P42 
P81 
P81 
P81 
P94 
P32 
P41 
N97 
++ 
48 
49 
53 
52 
38 
44 
42 
30 
42 
42 
41 
47 
50 
46 
41 
28 
54 
51 
106 
43 
41 
32 
57 
+-
o 
3 
4 
4 
3 
o 
9 
4 
6 
2 
2 
o 
2 
1 
2 
o 
o 
1 
o 
1 
2 
o 
o 
-+ 
5 
2 
2 
4 
13 
4 
3 
12 
3 
18 
8 
6 
8 
8 
14 
32 
12 
11 
25 
9 
10 
19 
51 
5 
6 
11 
7 
7 
5 
4 
14 
8 
5 
9 
6 
5 
4 
4 
2 
2 
3 
1 
2 
3 
2 
5 
x' 
26.26 
26.06 
37.86 
21.38 
4.95 
26.99 
5.52 
12.42 
17.84 
4.47 
18.98 
26.16 
12.97 
12.00 
4.42 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
AB2 
1213 
P62 
P81 
P21 
P21 
P21 
P21 
P42 
P81 
P22 
P22 
P42 
217 
P52 
P42 
P92 
++ 
4 
3 
13 
6 
4 
6 
6 
14 
32 
11 
9 
22 
5 
5 
13 
20 
TABLE 3. Examples of multiscreens on high-PRA patients 
Panel 
size 
568 
328 
491 
323 
345 
PRA 
82% 
79% 
87% 
94% 
93% 
AB 
P32 
P93 
P81 
P21 
P81 
P42 
? 
++ 
430 
252 
356 
49 
241 
58 
+-
35 
48 
18 
o 
8 
3 
-+ 
31 
8 
73 
24 
62 
4 
70 
20 
43 
43 
12 
9 
+-
o 
o 
o 
o 
o 
o 
o 
1 
o 
1 
o 
o 
o 
o 
o 
-+ 
1 
5 
2 
2 
2 
2 
o 
o 
1 
2 
3 
4 
5 
6 
37 
x' 
209.6 
47.9 
84.5 
50.0 
16.6 
32.6 
5 
5 
4 
9 
6 
5 
4 
4 
1 
2 
2 
1 
2 
3 
2 
5 
x' 
6.67 
5.62 
4.48 
10.43 
6.00 
6.96 
6.00 
18.00 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Undefined 
tail 
7% 
3% 
6% 
1% 
100% 
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information. For 24 of 38 patients (or 63%) with PRA values 
in the 90-100% range, it was possible to identify one or more 
HLA-specific antibodies. 
It is evident in Figure 1 that most high PRA sera showed a 
limited number of antibody specificities. They were primarily 
toward public and the more common private antigens. Table 4 
shows the distribution of public and private HLA determinants 
recognized in 132 high PRA patients with defined antibodies. 
They have been categorized into the different CREGs. There 
was a relatively even distribution among the antibodies specific 
for antigens in the combined A-locus and the combined B-Iocus 
CREGs. Public markers in the Al and A2 CREGs were recog-
nized 117 times, whereas in 121 instances a public marker in 
the combined B-Iocus CREGs was detected. A private antigen 
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FIGURE 1. Serum antibody specificity distribution among highly 
sensitized renal dialysis patients within different PRA ranges. 
was detected 50 times for the A locus and 41 times for the B 
locus. For the AI, A2, B5, B7, and B12 CREGs, the antibody 
specificities were more frequently toward the public markers 
than the private antigens. The exception is the B8 CREG, for 
which antibody specificity was primarily directed toward the 
private antigens rather than the public markers. Also somewhat 
surprising was the relatively low incidence of antibody specific-
ity toward Bw6 and its related P94 marker (Bw6 + All) in 
comparison to the frequencies of antibodies toward Bw4 and 
its related P81 marker (Bw4 + A9 + A32). Three public 
markers-P21, P22, and P92-were assigned on the basis of 
the specificity pattern of class I specific murine monoclonal 
antibodies (18). For each of them, we identified high PRA sera 
with specific antibody activity. It should be noted that no sera 
showed specificity toward any of the "nonsense" markers N97, 
N98, and N99. 
No attempt was made to determine associations between 
antibody specificity toward public and private determinants 
and the HLA-A,B type of the patient. Similar to observations 
by Kreisler et al. (21) and others (5, 10), we observed an 
increased frequency ofDR2 in high PRA patients (30% vs. 18% 
in nonsensitized renal dialysis patients, x2 = 6.25; P = 0.012). 
Undefined tail analysis of high-PRA sera. The multiscreen 
program also revealed how much panel reactivity of each serum 
had no demonstrable specificity toward any defined private or 
public HLA-A,B marker. The extent of this nonspecific reac-
tivity was assessed by the length of the undefined "tail," ex-
pressed as the percentage of positive reactions with no statis-
tically significant correlations. Figure 2 shows the distribution 
of undefined tails among patient sera within different PRA 
ranges. A tail of less than 5% was considered insignificant for 
nonspecific reactivity. Whereas a tail of 5-10% was suggestive 
TABLE 4. Distribution of serum antibody specificities toward public markers and private HLA-A,B determinants of the various crossreactive 
groups in 132 high-PRA patients 
No. patients with antibody specificity toward: Total No. of antibody specificities 
Group 
Public markers Private determinants Publics Privates Total 
A1CREG POI (14) ,P03( 1),P11 (6) ,P21 (10) A1(3),A3( 4),A10( 4) 68 19 87 (27.5%) 
P31(2),P71(6),P91(6),P93(10) A11(2),Aw19(2),A25(1) 
311(8),3031 (0),2532(0),1126(5) A30(1),A32(1),A33( 1) 
A2CREG P02( 20) ,P12(19) ,P22 (4) ,P32 (10) A2(18),A9(9),A23(2) 59 30 89 (27.1 %) 
217(6) A24(1) 
B5CREG P41(15),P51 (6),P61 (7) B15(2),B17(4),B35(l) 29 12 41 (12.5%) 
1517(1) B49(2) ,B53( 1) ,B57(2) 
Bw70(1) 
B7CREG P42(9) ,P52( 4),P62(3) B7 (4),B 13 (2) ,B41 (1), 23 9 32 (9.7%) 
722(1),727(2),740(3),1340(1) B55(1),B60(1) 
B8CREG P43(0),P63(0),P92(1),P95(0) B8(12),B14(3) 3 15 18 (5.5%) 
814(0),1622(2) 
B12 CREG P64(4),P72(12),P82(8), B12(3),B44(3) 31 6 37 (11.3%) 
1213(4),1221(3) 
Bw4 P81(17),Bw4(8) 25 25 (7.6%) 
Bw6 P94(3),Bw6(1) 4 4(1.2%) 
Totals 338 91 329 
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of residual undefined reactivity, we considered undefined tails 
of>lO% as significant evidence for non-HLA specific antibody 
activity. 
These significant tails were grouped according to their 
lengths: 11-20%, 21-60%, and 100% (no sera were found with 
tails from 61 to 99%). An undefined tail of 100% means that 
no antibody specificity could be determined in the multiscreen. 
In the group of 38 patients with >90% PRA values, there were 
14 (or 38 % ) whose sera were completely nonspecific as indicated 
by the 100% tails. The remaining 24 patients exhibited one or 
more antibody specificities in their sera (Fig. 1); for 20 of them 
the undefined tail was under 10% (Fig. 2). These data show 
that for 20 of 38 patients with greater than 90% PRA, we could 
define virtually complete specificity patterns of HLA antibod-
ies. 
Almost two thirds of patients in the 80-89% and 70-79% 
PRA groups showed nonspecific tails of less than 10%, sug-
gesting that computer-determined antibody specificity ac-
counted for more than 90% of their serum reactivity. Only a 
few patients in these PRA ranges had 100% nonspecific sera. 
The 50-69% PRA group showed a different distribution of 
undefined tails. Although all of 36 patients in this group exhib-
ited one or more antibody specificities (Fig. 1), only 12 (or 33%) 
showed undefined tails of less than 10%, a markedly lower 
percentage than that observed for the higher PRA groups. 
These somewhat unexpected findings suggest that a complete 
assessment of antibody specificity is more difficult for sera with 
50-69% PRA values. Studies are currently in progress to inves-
tigate the reactivity patterns of these sera. 
90-100 N=38 Length of 
Undefined Tall 
• <5% SO-89 N=47 C 
• a: 5-"10% ... 
.... 70-79 N=29 IIlI 11-20% 
121 21-60% 
50-69 N=36 121 100% 
20 40 60 80 100 
% of Patients 
FIG URE 2. Distribution of undefined serum reactivity tails of differ-
ent lengths for highly sensitized renal dialysis patients within different 
PRA ranges. 
DTE treatment of nonspecific sera. As noted above, 18 of 150 
patients (or 12%) showed only nonspecific antibody activity as 
indicated by the 100% undefined tails. The majority of these 
sera came from patients with >90% PRA values. It was postu-
lated that many such patients may have IgM type non-HLA 
specific lymphocytotoxic antibodies that could be inactivated 
by treatment with DTE. Preliminary results of serum -screening 
analysis of DTE-treated sera from 13 patients are summarized 
in Table 5. Most sera (but not all) showed a reduction in PRA 
activity after treatment with DTE. Although a much smaller 
cell panel was used for this screening analysis, HLA antibody 
specificity was detected in 9 of 13 DTE-treated sera, whereas 
one serum (from patient 22815) became essentially nonreactive. 
Renal transplant outcome in highly sensitized patients. From 
May 1985 to June 1989, a total of 92 renal transplants were 
performed on 89 of 150 highly sensitized patients. Donor selec-
tion did not depend on any information about the antibody 
specificity as described in this report. There were 32 primary 
transplants and 60 retransplants. A retrospective study was 
conducted to assess differences in survival of allografts from 
donors with computer-predicted acceptable and unacceptable 
HLA-A,B mismatches as determined from the serum antibody 
specificity defined by multiscreens. Figure 3 shows a consider-
ably lower survival rate of grafts from donors with unacceptable 
than with acceptable HLA-A,B mismatches. The differences in 
graft survival were seen primarily during the early posttrans-
plant period. About one half of the retransplants with unac-
ceptable HLA-A,B mismatches showed a precipitous graft fail-
ure within 60 days. The primary allograft failure rate was 
somewhat more gradual but still resulted in the loss of about 
one half of the transplants during the first 90 days posttrans-
plant. For the combined series of primary transplants and 
retransplants, the actuarial graft survival of transplants with 
unacceptable HLA-A,B mismatches was significantly lower 
than of those with acceptable mismatches (P = 0.01). Between 
these groups there were no significant differences in the PRA 
values (77.8 ± 2.7% vs. 73.2 ± 1.6%), crossmatch results (mean 
Terasaki scores: 1.41 ± 0.11 vs. 1.44 ± 0.16), number of HLA-
A,B mismatches (2.36 ± 0.28 vs. 2.24 ± 0.14), and number of 
HLA-DR mismatches (1.03 ± 0.09 vs. 1.13 ± 0.17). These data 
suggest that in highly sensitized patients kidney transplants 
from donors with computer-predicted unacceptable HLA-A,B 
mismatches have lower survival rates. 
TABLE 5. Reactivity and HLA antibody specificity of DTE-treated "nonspecific" high-PRA sera 
No treatment After DTE treatment 
Patient Antibody Panel size PRA Panel size PRA 
specificity % Tail 
8030 265 98% 101 92% P11,A9 2 
29825 261 98% 58 89% Bw4 31 
21068 569 97% 101 73% P52,B35 57 
22298 389 97% 58 82% Bw6 9 
16892 590 96% 101 98% Undefined 100 
11527 484 95% 101 89% P11 10 
23979 264 95% 101 89% P81,P42 0 
24560 516 95% 101 98% Undefined 100 
27100 388 95% 58 91% Undefined 100 
21357 261 94% 58 88% Bw4 30 
21476 391 94% 101 91% P12,P42? 15 
22815 326 88% 101 5% Nonreactive 
22694 496 83% 101 96% P01?,P02? 15 
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Renal allograft function was assessed by serum creatinine 
levels 2 and 4 weeks after transplantation (Fig. 4). This infor-
mation was collected from all patients transplanted since July 
1986. Creatinine levels were significantly higher in patients 
with transplants from donors with unacceptable HLA-A,B 
mismatches. These findings suggested that kidneys with unac-
ceptable mismatches had poorer function than kidneys with 
acceptable mismatches. Renal histopathology was available for 
35 high PRA patients with acceptable mismatched grafts and 
for 12 patients with unacceptable mismatches (Table 6). Hu-
moral rejection was significantly increased in kidneys with 
unacceptable HLA-A,B antigens. No differences between the 
groups were noted in the incidence of vascular lesions due to 
histologically diagnosed cellular rejection. 
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FIGURE 3. Actuarial graft survivals in highly sensitized patients 
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ceptable and unacceptable HLA-A,B mismatches. For the combined 
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TABLE 6. Incidence of histologically diagnosed humoral and cellular 
rejection of kidney transplants with acceptable and unacceptable 
HLA-A,B mismatches 
Humoral Cellular 
HLA-A,B match n rejection" rejection" 
+ + 
Acceptable 35 10 25 8 27 
Unacceptable 12 8 4 3 9 
• X2 = 7.83; P = 0.02. 
b X2 = 0.02; P = NS. 
Other aspects of the multiscreen program. As described above, 
this computer analysis program of serum screening yields the 
PRA value, antibody specificity information toward public and 
private class I HLA antigens, and the undefined tail of nonspe-
cific serum reactivity. It determines what donor HLA-A,B 
antigens must be considered unacceptable to potential recipi-
ents with preformed HLA specific antibodies. 
This program also generates information about significant 
negative correlations between serum reactivity and certain HLA 
antigens. As can be expected, many of these negative correla-
tions pertain to the patient's own HLA antigens and to those 
that are strongly crossreactive. Frequently, significant negative 
correlations have also been seen with noncrossreacting mis-
matched HLA-A,B antigens. Examples are shown in Table 7. 
These findings suggest that certain acceptable HLA-A,B mis-
matches might be preferable over others. Weare currently 
studying the effect 9f such preferred mismatches on transplant 
outcome. 
DISCUSSION 
The multiscreen serum analysis program permits a determi-
nation of serum antibody specificity for most highly sensitized 
transplant candidates. It incorporates two modifications into 
computer programs commonly used to determine the HLA 
specificity of allosera from multiparious women. One modifi-
cation implements the concept of public HLA determinants 
based on serologic crossreactivity among class I HLA antigens. 
The second modification derives from the premise that most 
highly sensitized patients maintain the same PRA and anti-
body-specificity profiles over many months and even years and 
deals with combining screening results of consecutive monthly 
sera if the PRA values remain similar. For the majority of 
highly sensitized patients, rather complete information is ob-
tained about serum-antibody specificity toward public and pri-
vate HLA class I antigens. This information is critical to the 
selection of suitable transplant donors because distinctions can 
be readily made between acceptable and unacceptable HLA 
antigens. 
It should be noted that the multiscreen program does not 
require any extra effort at the laboratory bench. Instead, it 
utilizes existing data from monthly serum screenings against 
HLA-typed cell panels. 
The primary objective of this computer program is to deter-
mine for highly sensitized patients which HLA-A,B antigens 
should be avoided in the selection of a suitable transplant 
donor. Using the Amos wash technique for serum screening, we 
have obtained information about antibody specificity against 
public markers and the more common private class I HLA 
antigens for almost 90% of patients with greater than 50% 
PRA. This has enabled an algorithm to identify computer-
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TABLE 7. Examples of significant negative correlations of high-PRA serum reactivity with mismatched private HLA-A,B antigens 
Patient HLA type PRA 
28559 A2,-;B35,63;DR5,6 74% 
14153 A3,29;B7,44 83% 
24714 A3,33;B42,-;DR4,8 89% 
20245 A2,3;B7,61;DR2,- 89% 
7530 A2,11;B18,35;DR3,- 91% 
predicted acceptable and unacceptable donor HLA-A,B anti-
gens for patients with preformed antibodies. Donors with un-
acceptable HLA antigens can be expected to give positive 
crossmatches with patient serum. In a future paper we will 
address the predictability of the outcome of the crossmatch test 
from the computer-assigned acceptable and unacceptable donor 
antigens. Using a similar approach to analyze serum antibody 
reactivity toward public and private class I antigens, Turka et 
a1. (22) observed a high computer predictability of positive but 
not of negative crossmatches. No data were given about the 
antibody specificities detected in their patient population. We 
believe that for high PRA patients with defined serum antibody 
specificities, the accuracy of a computer-predicted positive 
crossmatch is inversely correlated with the percentage of false-
negative reactions in the multiscreen, whereas the accuracy of 
a computer-predicted negative crossmatch is reflected by the 
length of the nonspecific tail of serum reactivity. 
The distinction between acceptable and unacceptable donor 
HLA antigen mismatches is relevant to transplant outcome. 
Our analysis of 89 highly sensitized transplant recipients has 
demonstrated that renal allografts with unacceptable mis-
matches were less successful than those with acceptable mis-
matches. This difference was shown not only by a lower graft 
survival rate but also by higher serum creatinine levels during 
the first month posttransplant and histopathologic evidence of 
humoral immune injury to the renal allograft. It should be 
noted that the failures of kidney transplants with computer-
predicted unacceptable class I HLA mismatches occurred pri-
marily during the early posttransplant period. 
These transplant data show that many patients had received 
renal allografts from donors with unacceptable HLA-A,B mis-
Mismatched HLA-A,B 
with significant negative 
Ab specificities correlations 
Antigen x' 
POI, A9, 740 A26 40.2 
Bw58 21.1 
A28 16.8 
B38 11.5 
P32, B17, B8 B14 71.8 
A30 48.4 
B42 18.1 
Aw33 17.6 
A31 12.0 
P32, P41 B7 39.5 
A30 37.6 
B14 10.1 
P81, P41, P82 B8 91.5 
Al 27.4 
Bw22 19.9 
A26 13.5 
P21, Aw19, P62 A28 53.9 
Bw41 27.4 
B14 24.7 
A3 16.2 
B39 7.8 
matches. Since the vast majority of the final crossmatches with 
those donors were negative, it must be concluded that our 
crossmatch methodology (i.e., Amos wash technique) might not 
have been sensitive enough to detect these unacceptable mis-
matches. A more sensitive assay such as antiglobulin augmen-
tation (23,24) or the flow cytometric crossmatch (25,26) might 
have detected these donor incompatibilities. On the other hand, 
more sensitive crossmatch assays are more likely to give false-
positive results, thereby excluding many high PRA patients 
from transplantation. Relevant to this problem is the frequency 
of "false-negative" reactions of many high PRA sera. As illus-
trated in Table 3, the multiscreen of the P32 specific serum 
from patient 21632 showed false-negative reactions with 35 of 
465 (or 8%) of P32 cells. It can be estimated that a potential 
donor with an unacceptable P32 mismatch would have an 8% 
chance of showing a negative crossmatch. Similarly, there 
would be a 16% chance of a false-negative crossmatch for 
patient 17793 when tested by conventionallymphocytotoxicity. 
Although there is no perfect crossmatch assay available at this 
time, it appears that information about serum antibody speci-
ficity is essential to the proper interpretation of the crossmatch 
results and the selection of suitable transplant donors for highly 
sensitized patients. The importance of the multiscreen program 
in donor-selection strategies is illustrated by the improved graft 
survivals of kidneys with computer-predicted acceptable HLA-
A,B mismatches: 67% vs. 44% for primary transplants and 68% 
vs. 50% for retransplants after 1 year (Fig. 3). These survival 
rates are still lower than those observed for nonsensitized 
patients at our institution (27). Although further refinements 
in public antigen definition may improve the computer predic-
tion of acceptable class I mismatches, we must also consider 
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the likely possibility that presensitization against class II HLA 
antigens will adversely affect transplant outcome in sensitized 
recipients. 
This computer program also generates information about 
significant negative correlations between serum reactivity and 
HLA antigens. Although many of these HLA antigens are the 
same as the patient's own or strongly crossreactive splits, others 
are noncrossreactive mismatches. The latter deserve special 
consideration in strategies to increase the number of potential 
donors with preferred acceptable mismatches. A similar strat-
egy has been used by Claas et a1. (10) who performed serum 
screenings with selected panel cells with only one HLA antigen 
mismatched to the patient. Its purpose is to identify which 
HLA antigens would not be recognized by patient serum. This 
approach is labor intensive, and the determination of accepta-
ble mismatched HLA antigens must be done by trial and error. 
Our computer analysis program offers the advantage of more 
readily identifying acceptable HLA-A,B mismatches. 
For 18 of 150 patients, we could not identify HLA-specific 
antibody by conventionallymphocytotoxicity screening. Many 
of these non-HLA specific sera appear to contain IgM type 
antibodies that can be inactivated by DTE (or dithiothreitol 
[DTT]) DTT) treatment. Following the initial studies by Iwaki 
et a1. (17) and Chapman et a1. (28), it is now generally recog-
nized that these nonspecific IgM lymphocytotoxins are clini-
cally unimportant in humoral rejection of renal transplants 
(29). This has been demonstrated by the good graft survivals 
of kidney transplants from donors with conventional cross-
match positive but DTT crossmatch negative donors. However, 
it has also become apparent that certain patients have HLA-
specific IgM-type antibodies that are sensitive to DTT treat-
ment (Duquesnoy RJ, Marrari M, White LT, et a1. Laboratory 
survey of serological crossmatching by the NIH, Amos wash, 
antiglobulin and flow cytometry procedures [manuscript in 
preparation]). Their clinical relevance in kidney transplanta-
tion is yet unclear, although it seems likely that some of these 
antibodies could induce humoral immune injury. Since our 
computer program can readily distinguish between HLA and 
non-HLA antibodies, it can be applied to determine which 
patient sera should be evaluated for DTT sensitivity. This 
pertains not only to completely nonspecific sera but also to 
sera with significant undefined reactivity tails. 
Computer assignment of public markers to our cell panel was 
based on the crossreactivity among groups ofHLA-A and HLA-
B antigens. This approach is limited by the empirical nature of 
the serologic studies to establish crossreactivity. Although 
workshop efforts have been directed toward a better serologic 
definition of public determinants (30), there is no recognized 
nomenclature documenting the polymorphisms. Considerable 
progress has been made with the molecular studies by Schwartz 
and co-workers (31,32) on the B5 and B7 CREGs and by Ayres 
and Cresswell (33) on Bw4/Bw6, demonstrating that public 
determinants represent epitopes distinct from the private de-
terminants. More recently, the investigations by Parham and 
co-workers (34, 35) have provided detailed information about 
the amino-acid sequences and location of public and private 
epitopes on the HLA peptide, primarily on the ll!j and ll!2 
domains. Such studies will undoubtedly improve the definition 
of public epitopes on class I molecules expressing the different 
private HLA-A and HLA-B specificities, thereby increasing the 
efficiency of antibody-specificity analysis of sera from highly 
immunized patients. 
A common strategy to increase the opportunity for trans-
plantation of high PRA patients has been through serum ex-
changes between collaborating transplant centers for the pur-
pose of finding crossmatch negative donors (5, 8, 9). Although 
this approach has led to successful transplants, severallogisti-
cal problems prevent its widespread implementation. These 
difficulties relate to differences in sensitivity of crossmatch 
tests in the various laboratories, availability of current sera for 
final crossmatching, and delays in donor organ transportation 
causing prolonged ischemia time. Moreover, crossmatching is 
done randomly and rarely considers the antibody specificity of 
the patient's serum. With the computer analysis program de-
scribed in this report, it would be possible for regional organ-
sharing programs to develop a file of high PRA patients, each 
of whom will have a list of acceptable and unacceptable donor 
HLA-A,B antigens as determined from the antibody specificity 
of their sera. This approach would eliminate the need for 
distribution of patient sera to other tissue-typing centers. Given 
the HLA type ofthe potential donor, it would be relatively easy 
to determine the most suitable candidates for whom a final 
crossmatch is likely to be negative. Donor selection should also 
consider HLA-DR compatibility to increase renal allograft 
survival in highly sensitized patients (36-38). 
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